Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.46 |
| ▸ | PARP14 | Q460N5 | 3/20 | 0.46 |
| ▸ | TNKS | O95271 | 10/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6646094 | 0.92 | TNKS (0.50) | PARP1PARP14TNKSCCNT1CDK9 | |
| SCHEMBL13107353 | 0.84 | PARP1 (0.49) | PARP1PARP14TNKSCCNT1CDK9 | |
| SCHEMBL13107354 | 0.84 | PARP1 (0.49) | PARP1PARP14TNKSCCNT1CDK9 | |
| SCHEMBL3441929 | 0.84 | PARP1 (0.49) | PARP1PARP14TNKSCCNT1CDK9 | |
| SCHEMBL6645436 | 0.83 | PARP1 (0.44) | PARP1PARP14TNKS | |
| SCHEMBL3443059 | 0.83 | PARP1 (0.48) | PARP1TNKSCCNT1CDK9 | |
| SCHEMBL6642750 | 0.82 | PARP1 (0.43) | PARP1PARP14TNKS | |
| SCHEMBL6644488 | 0.82 | KDM4E (0.46) | PARP1PARP14TNKSKDM4EATM | |
| SCHEMBL3442404 | 0.81 | TNKS (0.54) | PARP1TNKSATM | |
| SCHEMBL6647500 | 0.81 | TNKS (0.46) | PARP1PARP14TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | claimed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | claimed |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | PARP11, PARP1, CD38 | PARP1 2/4885PARP14 10/4885TNKS 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.